Target Gene/Pathway(薬物標的遺伝子/パスウェイリスト)
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z other
No. | KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * | KEGG DRUG * | DrugBank | 指定難病告示番号 * |
1 | Cytokine-cytokine receptor interaction |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
2 | EGFR tyrosine kinase inhibitor resistance |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
3 | Hematopoietic cell lineage |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
4 | HIF-1 signaling pathway |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
5 | Human cytomegalovirus infection |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
6 | JAK-STAT signaling pathway |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
7 | Non-alcoholic fatty liver disease (NAFLD) |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
8 | Pathways in cancer |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
9 | PI3K-Akt signaling pathway |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
10 | Th17 cell differentiation |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
11 | Viral protein interaction with cytokine and cytokine receptor |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |